logo

Biohaven Pharmaceutical Holding Co Ltd. (BHVN)



Trade BHVN now with
  Date
  Headline
9/10/2019 7:31:36 AM Biohaven Announces Completion Of Enrollment Of Pivotal Phase 2/3 Trial Of Vazegepant
8/7/2019 7:44:37 AM Biohaven Completes Enrollment In Pivotal Phase 3 Preventive Treatment Of Migraine Trial
7/22/2019 7:34:50 AM Biohaven Says Enrollment In T2 Protect AD Study Is Progressing On Timelines
7/15/2019 7:33:08 AM Biohaven Publishes Positive Phase 3 Trial Of Rimegepant Zydis For Acute Treatment Of Migraine In The Lancet
7/1/2019 7:31:56 AM Biohaven Enrolls First Patient In Phase 2 Clinical Trial Of Rimegepant, Oral CGRP Receptor Antagonist
6/24/2019 7:31:43 AM Biohaven To Present 16 Abstracts At 2019 American Headache Society AHS Highlighting New Data With Rimegepant
6/18/2019 10:13:47 PM Biohaven Pharmaceutical Announces Pricing Of Underwritten Public Offering Of 6.98 Mln Shares At $43.00/shr
6/17/2019 7:46:48 PM Biohaven Announces Proposed Public Offering Of Common Shares
5/7/2019 11:29:36 PM Biohaven Says Advances Late Stage Clinical Programs And Novel Targets From Neuroinnovation Platforms
5/7/2019 7:08:14 AM Biohaven Pharmaceutical Q1 Net Loss Narrows To $62.3 Mln Or $1.41/shr From $85.5 Mln Or $2.32/shr Last Year
5/3/2019 7:42:54 AM Biohaven Announces Late-Breaking Oral Presentation Of Rimegepant Zydis ODT Phase 3 Results
3/14/2019 7:32:25 AM Biohaven Enrolls First Patient In Phase 3 Spinocerebellar Ataxia Clinical Trial Of Troriluzole
3/13/2019 7:34:01 AM Biohaven Announces Completion Of Pre-NDA Meeting With FDA For Oral CGRP Receptor Antagonist Rimegepant
2/19/2019 7:32:42 AM Biohaven' Verdiperstat Gets Orphan Drug Designation From FDA For Multiple System Atrophy
2/4/2019 7:36:50 AM Biohaven Says Administration Of Intranasal BHV-3500 In Phase 1 Trial Achieved Targeted Therapeutic Exposures
  
 
>